ondansetron has been researched along with Hyperpigmentation in 1 studies
Ondansetron: A competitive serotonin type 3 receptor antagonist. It is effective in the treatment of nausea and vomiting caused by cytotoxic chemotherapy drugs, including cisplatin, and has reported anxiolytic and neuroleptic properties.
Hyperpigmentation: Excessive pigmentation of the skin, usually as a result of increased epidermal or dermal melanin pigmentation, hypermelanosis. Hyperpigmentation can be localized or generalized. The condition may arise from exposure to light, chemicals or other substances, or from a primary metabolic imbalance.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Iglesias, ME | 1 |
| España, A | 1 |
| Redondo, P | 1 |
| Quintanilla, E | 1 |
1 other study available for ondansetron and Hyperpigmentation
| Article | Year |
|---|---|
Fixed drug eruption secondary to ondansetron.
Topics: Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Drug Eruptio | 1995 |